Leukocyte procoagulant activity (PCA) is accepted as an important component in the onset of disseminated intravascular coagulation (DIC). DIC is common in acute promyelocytic leukemia (APL) and other forms of cancer[1-5]. DIC in cancer patients is often observed after initiation of therapy with cytotoxic oncology drugs that act by altering DNA replication (e.g., doxorubicin, daunorubicin, and vincristin)[9-12]. Cytotoxic drugs (doxorubicin, daunorubicin and vincristin) and endotoxin have previously been shown to induce leukocyte PCA in vitro and DIC in vivo[13-21]. In vitro, doxorubicin-induced leukocyte PCA has previously been linked to DIC in vivo [3].

• NCL_Method_ITA-17_June2020.pdf(PDF | 398 KB)

Researchers should cite this work as follows:

• Timothy Potter, Edward Cedrone, Barry Neun, Marina Dobrovolskaia (2020). NCL Method ITA-17. (Version 2.0). NCI Hub. doi:10.17917/F32N-3W57

  BibTex | EndNote

1. DIC
2. Nanoparticles
3. procoagulant activity